Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000, Australia
Signatory: Julian Babarczy, Chairman (Dated June 15, 2026)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate action rather than a financial statement.
Material Changes
The primary material event disclosed is the cessation of securities trading for the ticker symbol "ATH," as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implication of the cessation of securities. The document is incorporated by reference into Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the official reason for the cessation of securities trading for ticker "ATH" via the attached Exhibit 99.1.
- Confirm the current trading status of Alterity Therapeutics Limited shares on relevant exchanges.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on outstanding equity plans.
- Check for subsequent filings regarding the company's operational status as a development stage enterprise.